Piramal Healthcare has acquired New York-based Minrad International, a manufacturer of generic inhalation anaesthetic drugs for $40 million.

Under the arrangement, the shareholders of Minrad will receive $0.12 a share in cash and Piramal will also acquire Minrad's 8 per cent senior secured convertible notes from the note holders.

Aurobindo Pharma, an Indian private pharmaceutical company, informed that it has got tentative sanction from US Food & Drug Administration (USFDA) to make and sell fixed dosed combination Abacavir Sulfate/ Lamivudine Tablets.

The company has been allowed to manufacture the drugs in the strengths of 60/30 mg.

Abacavir sulfate tablets are indicated for the treatment of HIV infection in adults and children 3 months of age or older.

Ranbaxy Laboratories and its new owner Japan’s Daiichi Sankyo, which now holds 63.92% of Ranbaxy’s equity share capital, reconstituted a new 10-member panel.

From the company’s earlier 15 member panel, the company retained only three members including former owner Malvinder Singh, COO Atul Sobti and Religare CEO & MD Sunil Godhwani.

The newly announced board reflects the changed ownership structure at Ranbaxy, following Daiichi Sankyo’s strategic investment during the last month (Nov 2008).

Aurobindo Pharma, a leading drug manufacturer, has announced that it has got tentative sanction from the US Food and Drug Administration (USFDA) for PerindopriL Erbumine tablets.

The approval has been granted for 2 mg, 4 mg and 8 mg dosage of drug.

According to the sources, PerindopriL Erbumine tablets are indicated for the treatment of high blood pressure.  
 
The sources further revealed that the conglomerate has also received tentative approval for Escitalopram Oxalat Oral solution 5 mg base/5 ml.  

Ranbaxy Laboratories Ltd, a leading pharmaceutical major, has announced that it has clinched an exclusive licensing pact with US-based BioPro Pharmaceutical to market Gliadel tablets in India.

Earlier, Ranbaxy had announced a similar agreement with CD Pharma, a leading Europe-based  biotech  firm to sell its probiotic dental medicine Inersan in India and  Nepal.